The mechanisms that are responsible for the restricted pattern of expression of the VE-cadherin gene in endothelial cells are not clearly understood. Regulation of expression is under the control of an approximately 140 bp proximal promoter that provides basal, nonendothelial specific expression. A larger region contained within the 2.5 kb genomic DNA sequence located ahead of the transcription start is involved in the specific expression of the gene in endothelial cells. We show here that the VE-cadherin promoter contains several putative hypoxia response elements (HRE) which are able to bind endothelial nuclear factors under normoxia. The VE-cadherin gene is not responsive to hypoxia but hypoxia-inducible factor (HIF)-2a specifically activates the promoter while HIF-1a does not. The HRE, that are involved in this activity have been identified. Further, we show that HIF2a cooperates with the Ets-1 transcription factor for activation of the VE-cadherin promoter and that this synergy is dependent on the binding of Ets-1 to DNA. This cooperative action of HIF-2a with Ets-1 most probably participates to the transcriptional regulation of expression of the gene in endothelial cells. This mechanism may also be involved in the expression of the VE-cadherin gene by tumor cells in the process of vascular mimicry.
Introduction
Endothelial cells form the inner layer of all blood vessels, they express several molecular markers that characterize the endothelial phenotype, such as the VEGF receptor flk-1 (Millauer et al., 1993) , the angiopoietin receptor Tie-2 (Sato et al., 1993; Schnu¨rch and Risau, 1993) , VE-statin , or VE-cadherin (Lampugnani et al., 1992) . VE-cadherin expression is mostly restricted to endothelial cells. This gene codes for a homophilic transmembrane glycoprotein that is essential to the formation of intercellular junctions and to endothelium integrity (Lampugnani et al., 1992; Navarro et al., 1995; Breier et al., 1996) . In vitro, VE-cadherin is involved in the regulation of endothelium density at confluence and inhibition of survivin expression (Iurlaro et al., 2004) . In vivo, VE-cadherin endocytosis is one of the molecular mechanisms, by which VEGF induces endothelium permeability (Gavard and Gutkind, 2006) . Disruption of endothelial contacts by the use of blocking antibodies against VE-cadherin induces endothelium permeability (Gulino et al., 1998) and rapid death (Corada et al., 1999) . Further, the N-terminal domain of VE-cadherin is a potential target against tumor vascularization; it is transiently accessible during tumor angiogenesis and blocking with an antibody inhibits tumor growth (May et al., 2005) . During normal development, VE-cadherin gene inactivation in mice results in mid-gestation embryonic death illustrated by a lack of formation of the early capillary plexus from the blood islands, a reduced capillary remodeling and endothelial cell apoptosis (Carmeliet et al., 1999; Gory-Faure´et al., 1999) . Expression of the VE-cadherin gene is controlled by a basal, non cell-specific promoter that lies within the À139/ þ 24 region of the gene. This region contains an active GT box and two Ets-binding sites (EBS), named EBS2 and EBS4, which are essential for expression (Gory et al., 1998) . We have shown previously that overexpression of the Ets-1 transcription factor induces VE-cadherin expression by direct binding to these two EBS (Lelie`vre et al., 2000) . The region that is responsible for the specific expression in endothelial cells is located in the À2486/ þ 24 part of the gene. This region is sufficient to drive endothelial expression of a reporter gene in vivo, though not in all organs . Further, a 4 kbp enhancer was identified in intron 1, which, together with the above 2.5 kb promoter, increases expression in endothelial tissues in vivo, but the enhancer elements that are responsible for its activity have not been identified (Hisatsune et al., 2005) .
We noticed that the promoter of the VE-cadherin gene contains several putative hypoxia response elements (HRE), suggesting that VE-cadherin could be regulated by the lack of oxygen. HRE are recognized by the hypoxia-inducible factors (HIF) family of basic helix-loop-helix-Per-Arnt-Sim transcription factors, composed of HIF-1a, HIF-2a and HIF-3a. HIF-1a was originally identified as the transcription factor that, under hypoxia, translocates to the nucleus as a dimer with HIF-1b/ARNT, and binds to the HRE of the hypoxia-sensitive 3 0 -enhancer of the erythropoietin gene (Semenza et al., 1991; Semenza, 1993, 1995; Jiang et al., 1996) . HIF-1a was subsequently shown to be involved in the activation of most hypoxic-responsive genes (for review, see Semenza, 2003) . HIF-1a is a highly unstable protein that undergoes rapid degradation in normal oxygen levels, due to hydroxylation of two prolines (Ivan et al., 2001; Jaakkola et al., 2001) by the oxygen-dependent prolyl-4-hydroxylases (Bruick and McKnight, 2001 ). Hydroxylation allows the factor to interact with the von HippelLindau protein and targets it to degradation by the ubiquitin/proteasome pathway. This process is also dependent on the formation of a ternary complex between HIF-1a, prolyl-hydroxylases and OS-9 (Baek et al., 2005) . Hypoxic conditions reduce the rate of prolyl-hydroxylases activity, thus reducing HIF-1a degradation and allowing HIF-1 target genes regulation (Kaelin, 2002) .
The HIF-1a homolog HIF-2a was originally characterized as being preferentially expressed in endothelial cells of highly vascularized tissues during development and in the adult (Ema et al., 1997; Flamme et al., 1997; Tian et al., 1997; Jain et al., 1998) . As for HIF-1a, the stability of the protein is increased in hypoxic conditions, whereas expression of the messenger RNA is not affected by variations in O 2 levels (Wiesener et al., 1998) . Although it later became clear that HIF-2a expression is not strictly restricted to the endothelium (Rosenberger et al., 2002; Wiesener et al., 2003) , HIF-2a gene inactivation leads to defaults in vascular remodeling during development and cardiac malfunction (Tian et al., 1998; Peng et al., 2000; Duan et al., 2005) , suggesting that HIF-2a plays a major role in endothelial cells during development. The third gene of the HIF factor family that was identified (HIF-3a) gives rises to six different transcripts, which code for various HIF-3a isoforms that differ in domain composition (Maynard et al., 2003) . The exact role of this third family of proteins is not known. Most human tumors analysed express detectable levels of HIF-1a and HIF-2a proteins, while normal tissues are generally negative, safe for macrophages (Talks et al., 2000) . Further, high HIF-2a levels are correlated with advanced stage and poor patient outcome in several tumor forms (Lofstedt et al., 2007) .
Here, we have analysed the response of the VEcadherin gene to hypoxia and to HIF-1a and HIF-2a. We show that HIF-2a, not HIF-1a, activates the VEcadherin gene promoter, mainly through one stretch of HRE located in the À2486/ þ 24 region of the promoter. This activation is independent of hypoxia. HIF-2a acts synergistically with the Ets-1 factor for transactivation of the promoter through two proximal EBS that are necessary for expression of the gene.
Results
The À2486/ þ 24 promoter region of the VE-cadherin gene contains several putative HRE (nRCGTGn, Semenza et al., 1996) , including four single sites (HRE6; À2119, HRE5; À1733, HRE2; À653, HRE1; À524, Figure 1 ), one head-to-head tandem (HRE3; À849/À839) and a stretch of 10 concatenated sites (HRE4; À1580/À1534), suggesting that the gene may be regulated by hypoxia or by the HIF family of transcription factors. We analysed the response of the VE-cadherin gene to hypoxia in mouse endothelial H5V cells. No significant changes in VE-cadherin expression (P>0.05) were observed in cells cultured under hypoxia for 6 or 18 h (Figure 2 ), whereas expression of VEGF was strongly increased, as expected for this hypoxiaregulated gene (Shweiki et al., 1992) . We then checked whether the putative HRE were able to bind endothelial nuclear proteins using electromobility-shift assay (EMSA). All HRE, except HRE6, specifically-bound nuclear factors in normoxic conditions (Figure 3 , arrowheads). As anticipated from the lack of response of the gene to hypoxia, no detectable changes in binding were seen in hypoxic conditions using either HRE probe. HRE6 showed no specific binding in normoxic or in hypoxic conditions. Super-shift experiments revealed that binding to HRE4 was partly disrupted by adding an anti-HIF-2a antibody whereas equal amounts of anti-HIF-1a antibody had no effects under similar conditions ( Figure 3) .
Next, we analysed the response of the promoter to the HIF-1a and HIF-2a transcription factors. Cells were transfected with increasing amounts of HIF-1a or HIF-2a expression vectors and with the À2486Luc VE-cadherin reporter vector which contains the À2486/ (Figure 4 , inset). HIF-1a did not induce any significant transactivation of the promoter over control at the tested doses, whereas HIF-2a induced a strong dose-effect activation of the reporter (Figure 4a ). Since HIF proteins are rapidly degraded under normoxic conditions (BrahimiHorn et al., 2005) , it seemed possible that the lack of response of the VE-cadherin promoter to HIF-1a could be due to a faster rate of degradation of HIF-1a than of HIF-2a. To stabilize both factors, we performed a similar experiment under hypoxic conditions. Hypoxia induced a moderate increase in HIF-1a activity on the VE-cadherin promoter when compared to normoxia, rising from 1.2570.0-to 1.970.1-fold, respectively ( Figure 4b ). Again, transactivation in normoxia using HIF-2a induced a stronger increase in promoter activity than when using HIF-1a (7.870.1-fold over control) and the levels of activation were not substantially different in hypoxic conditions (6.370.3-fold). To verify further that the HIF-1a expression vector used produced a functional protein, we transfected 3T3 cells with or without the HIF-1a expression vector and with VEGF promoter reporter constructs that contained (VEGF H-RE þ Luc) or not (VEGF HREÀ Luc) one of the reported active HRE of this gene (Forsythe et al., 1996) . In the presence of HIF-1a, the VEGF HRE þ Luc was activated 58.175.5-fold over control in normoxia ( Figure 5 ) and upregulated 117.075.1-fold in hypoxic conditions, as expected. The VEGF HREÀ Luc vector, which lacked one HRE, showed a response to HIF-1a in normoxia (39.272.0-fold) similar to that of VEGF HRE þ Luc, but responded half-less to HIF-1a under hypoxic conditions (59.274.4-fold), as expected (Forsythe et al., 1996) . The control pGL3basic vector was not noticeably activated by HIF-1a either in normoxic (1.170.0-fold) or in hypoxic conditions (1.270.1-fold), nor did it respond to hypoxic conditions alone (1.070.2-fold). These results thus show that the HIF-1a expression vector used allowed the expression of a functional protein and that the differences in response of the VE-cadherin promoter constructs to HIF factors cannot be attributed to a defective HIF-1a expression system. Taken all together, the above results show that the VE-cadherin promoter is specifically activated by HIF2a and not by HIF-1a. Further, the transcriptional activity of HIF-2a on the regulation of VE-cadherin is not affected by lowering the concentrations of oxygen.
To identify the promoter regions, which are responsible for the specific activation of the gene by HIF-2a, we constructed several reporter vectors that corresponded to 5 0 -deletions of the promoter, sequentially deleting each predicted HRE (Figure 1 P-labelled probes corresponding to the various HRE identified on the VEcadherin promoter sequence and analysed by electromobility-shift assay (EMSA). A 50-fold molar excess of unlabelled wild-type probe (wt) or of probe mutated on the HRE core sequence (mt) was added to assess specific (arrowheads) and non-specific binding, respectively. Antibodies (5 mg) against HIF-1a or HIF-2a were added to free probe (p) or to nuclear extracts (NE) samples. Except for HRE4, only the upper part of the gels are shown, p; probe lane, f; free probe.
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A Le Bras et al further the response of the promoter to HIF-2a to 4.670.1-and 3.870.2-fold, respectively. Removal of the last predicted HRE (HRE1) had no significant effect on activity (4.170.4-fold). Similar experiments were performed using HIF-1a, to check whether removal of the distal parts of the promoter regions, including those which responded to HIF-2a, would allow a response of the promoter to the factor. No significant activity of HIF-1a was observed on either reporter construct ( Figure 6 ), confirming that HIF-1a is not active on the VE-cadherin promoter or deletion fragments. We then checked the importance of the identified sites by analyzing the effects of null-mutations or region deletion (HRE4) on the response of the promoter to HIF-2a. Mutation of HRE6 or HRE5 did not result in any significant modification of the response of the promoter to HIF-2a (Figure 7 ), whereas deletion of HRE4 resulted in a 33% decrease in the response of the promoter to HIF-2a. Mutation of the HRE3 tandem had no significant effects on transactivation, thus confirming that the major site activated by HIF-2a is the stretch of 10 HRE corresponding to HRE4.
Finally, and to understand the fact that the À139/ þ 24 region of the promoter responded to HIF-2a although we could not identify any canonical HRE in its sequence (Figure 6 ), we checked whether HIF-2a could cooperate with Ets-1 to activate this region. This was based on our previous observation that Ets-1 is able to activate this region (Lelie`vre et al., 2000) and on the fact that Ets-1 was shown to interact with HIF-2a and to activate synergistically the flk-1 gene promoter (Elvert et al., 2003) . Ets-1 and HIF-2a used alone activated the À2486Luc reporter 4.870.1-and 8.870.2-fold, respectively (Figure 8 ), while transfection of Ets-1 and HIF-2a VE-cadherin responds to ETS factors, including Ets-1, through two essential EBS, named EBS2 and EBS4, which are located in this proximal part of the promoter (Gory-Faure´et al., 1999; Lelie`vre et al., 2000) . Mutation of either EBS2 or EBS4 abolished the synergy between Ets-1 and HIF-2a (Figure 8 ), yielding almost precisely 
A Le Bras et al the values calculated for an additive effect. In addition, mutation of both EBS2 and EBS4 resulted in a 76% reduction in the response to HIF-2a in the presence of Ets-1, an effect that could be explained by a dominantnegative effect of Ets-1, which does not bind to this DNA region anymore and that may titrate HIF-2a under these conditions. Most interestingly, the response of the EBS2/4m double mutant to HIF-2a alone remained unaffected when compared to the wild-type promoter. This suggests that the synergy between the transfected HIF-2a and endogenous Ets-1 on EBS2 and EBS4 is not solely responsible for the activation of the promoter in these conditions and that HIF-2a probably also activates this region of the gene through other sites and interactions, independently of Ets-1.
Discussion
The present work shows that the VE-cadherin gene is not regulated when endothelial cells are maintained in hypoxic conditions but that it is nevertheless specifically activated by HIF-2a and not by HIF-1a. Further, HIF-2a is able to activate not only the stretch of HRE located at À1580/À1534 relative to the transcription start, but also the À139/ þ 24 promoter region that is devoid of bona fide hypoxia-response elements. In this region, HIF-2a acts synergistically with the Ets-1 transcription factor, a synergy that depends on binding of Ets-1 to DNA.
The À2486/ þ 24 promoter region of the VE-cadherin gene is essential to its specific expression in endothelial cells; it is sufficient to drive the expression of a reporter gene in endothelial cells in vitro and in vivo, notably because of the presence of two domains (À140/À289 and À1190/À2226) that repress expression in nonendothelial cells . Interestingly, the À1190/À2226 domain used in this latter study encompasses the HIF2a-responding HRE4 stretch identified here, suggesting that HRE4 could participate to the repressive regulation of expression in non-endothelial cells. The VE-cadherin gene also contains a minimal (basal) promoter sequence, located in À139/ þ 24, which is active independently of the cell type (Gory et al., 1998 . This promoter region is mainly regulated by a set of two EBS and a GT-box, which are necessary for the basal activity of the gene (Gory et al., 1998) , both EBS being activated by Ets-1 isoforms (Lelie`vre et al., 2000; Lionneton et al., 2003) . Interestingly, this part of the promoter does not contain any conventional HRE but still responds to HIF-2a to a significant extent (Figure 6 ), suggesting that coactivation of HIF-2a with another transcription factor independently of its binding to DNA could promote transcription of the gene or that unknown, specific, HIF-2a-response elements are activated in this region. Both situations might actually exist because, first, we found that Ets-1 and HIF-2a cooperatively activate the VE-cadherin promoter, as seen with the flk-1 promoter (Elvert et al., 2003) , with a greater synergy here (1.8 time here versus 1.3-1.4 times on flk-1). On the flk-1 promoter, the synergy with Ets-1 was independent from binding of HIF-2a to DNA. We show here that this synergy is however dependent on the ability of Ets-1 to bind to DNA, as it depends on the integrity of the two EBS that are essential for gene expression and for Ets-1 binding (Gory et al., 1998; Lelie`vre et al., 2000) . Second, mutation of both EBS2 and EBS4 did not affect the response of the construct to HIF-2a alone, excluding the possibility that HIF-2a activity is dependent on its interaction with endogenous Ets-1 and rather suggesting that HIF-2a binds to DNA and activates the promoter through unidentified and non-conventional HIF-binding sites. The occurrence of such HIF-2a specific binding sites that would differ in sequence from the core HRE has already been proposed (Wang et al., 2005) but their existence is still not documented.
Since the VE-cadherin promoter responds to HIF-2a but not to hypoxia, the regulation of genes by HIF-2a must be, at least in some instances, independent of the oxygen levels. Several recent reports analyzing the genes that are regulated by hypoxia, by HIF-1 or by HIF-2 showed that HIF-1 is the main inducer of glycolytic genes expression and that it may be considered as the central transcriptional regulator of the cell 'hypoxic response', while most HIF-2a only responsive genes are not regulated by hypoxia (Hu et al., 2003; Sowter et al., 2003; Wang et al., 2005) . It is noteworthy that HIF-2a transcriptional activity is not strongly activated by hypoxia and may even be repressed, whereas that of HIF-1a is strongly induced under such conditions (O'Rourke et al., 1999). 
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The idea that HIF-2a regulates a different set of genes than HIF-1a has been clearly emerging. Owing to its sequence and organization similarities with HIF-1a, HIF-2a was initially assumed to bind to similar DNA sites and to activate a common set of genes (O'Rourke et al., 1999) . Later, reports suggested that the two factors have separate target genes; the use of specific siRNA targeted at HIF-1a or HIF-2a or HIF isoforms overexpression in cells showed that expression of most of the glycolytic genes in hypoxia is under the dependence of HIF-1a and not HIF-2a (Wang and Semenza, 1993; Hu et al., 2003; Sowter et al., 2003) , while genes such as VEGF or N-myc downstream regulated-1 (Hu et al., 2003) are regulated by both isoforms. Although no specific HIF-2a-regulated genes were identified in these studies, other recent reports showed that HIF-2a could indeed up and downregulate a different set of genes than HIF-1a in HEK-293 cells (Wang et al., 2005) and in renal carcinoma cells (Raval et al., 2005) . HIF-1a has been shown to activate specifically the glycolytic enzymes PGK and aldolase A, while Oct-4, a transcription factor involved in maintaining pluripotentiality of ES cells, appears to be regulated by HIF-2a but not by HIF-1a (Hu et al., 2003; Covello et al., 2005 Covello et al., , 2006 .
Whereas these studies addressed the downstream effects of modifying the expression of the HIF factors, a small number of promoters have been analysed for their direct response to HIF-2a. HIF-2a specifically regulates the angiopoietin receptor Tie-2 gene, but the binding sites are not identified (Tian et al., 1997) . HIF2a also specifically activates the eNOS promoter, by direct binding to two contiguous HIF-binding sites located À5375/À5366 bp ahead of the transcription start (Coulet et al., 2003) . Finally, HIF-2a activates the promoter of the VEGF receptor flk-1 through two HRE-EBS tandems located in the proximal (À140/À78) region of the promoter (Elvert et al., 2003) .
It is quite remarkable that the four genes which were shown to be directly controlled by HIF-2a (Tie-2, flk-1, eNOS and VE-cadherin here) are acknowledged endothelial cell markers and are specifically or quasispecifically expressed in these cells during development. This suggests that HIF-2a participates to the mechanisms by which these genes are expressed in endothelial cells, as for Ets-1. Ets-1 has been originally isolated as the cellular progenitor of v-ets, a viral oncogene found in the genome of the E26 acute leukaemia retrovirus, and later shown to be expressed in endothelial cells during development and during angiogenesis in the adult. Expression of Ets-1 is, however, not restricted to the endothelium as it is also expressed in the lymphoid organs of neonatal and adult mice, in somites and migrating neural crest cells in the embryo and in stromal fibroblasts of invasive tumors (for review see Lelie`vre et al., 2001) . Therefore, though Ets-1 is not specific to the endothelium, it is prominently expressed in endothelial cells during angiogenesis. Beside this apparent lack of strict specificity, the factor was clearly shown to be essential to the regulation of endothelial specificity of expression of flk-1 (Elvert et al., 2003) and able to regulate many other endothelial genes such as VEcadherin (Lelie`vre et al., 2000) , angiopoietin 2 (Hegen et al., 2004) or neuropilin-1 (Teruyama et al., 2001) . From these observations, we may hypothesize that by their preferential, though not strict, pattern of expression in endothelial cells, HIF-2a and Ets-1 bring a minimal level of endothelial specificity of gene expression. A second level of specificity is then necessary to more tightly restrict expression of these genes in endothelial cells, by yet unknown mechanisms. The supplementary levels of specificity may be given by cooperative action of Ets-1 or HIF-2a with other transcription factors, and probably by epigenetic regulatory mechanisms as well.
Materials and methods
Mouse heart H5V endothelioma and 3T3 fibroblasts were kindly provided by Dr P Huber (CEA Grenoble, France). pcDNA3-hHIF-1a was provided by Dr Max Gassman (University of Zurich, Switzerland), pcDNA3-hEPAS-1 (HIF-2a) by Dr David Russell (University of Texas Southwestern Medical Center, Dallas, USA). The VE-cadherin luciferase reporter vectors À2486Luc, À2486EBS2m, À2486EBS4m and À2486EBS2/4m were described previously (Lelie`vre et al., 2000) . Synthetic oligonucleotides were from Genosys (Sigma, Saint-Quentin Fallavier, France). Paired sample t-test statistical analysis was performed using Analyze-it software.
Cell culture Cells were cultured following standard conditions in a humidified 5% CO 2 /95% air atmosphere. For hypoxia experiments, the cell dishes were placed in a pressurized container which was extensively flushed with a gas mix composed of 1% O 2 /5% CO 2 /94% N 2 (Air Liquide, France). The container was then placed at 371C in a dedicated cell culture incubator for the indicated amount of time.
Transactivation assays Cells were seeded in 10 cm 2 culture dishes (150 000 cells/well) and transfected the next day with the indicated amounts of vectors using Exgen500 (Euromedex, Souffelweyersheim, France) in OptiMEM medium (Invitrogen, Cergy-Pontoise, France). After 6 h, the medium was changed for complete culture medium and the cells cultured for 2 days at which time extracts were prepared in Reporter Lysis buffer (Promega, Charbonnie`res, France). Luciferase and b-galactosidase activities measured using a Lumat luminometer (Berthold, La Garenne-Colombes, France).
Western blotting 3T3 cells were transfected with HIF-1a or HIF-2a expression vectors in the same conditions as for transactivation assays, lysed in phosphate buffer saline, 1% Igepal CA-630, 0.5% sodium deoxycholate, 0.1% SDS and protease inhibitors (complete, Roche, Meylan, France). Cell extracts were separated by 7.5% SDS-PAGE followed by blotting on nitrocellulose (Whatmann Schleicher-Schuell, Versailles, France) and analysed with a mouse anti-HIF1a (BD-Transduction Laboratories, Le Pont de Claix, France), a rabbit antiHIF2a (Novus biologicals, Interchim, Montlucon, France) or a goat anti-actin (Santa-Cruz, TEBU, Le Perray en Yvelines, France) antibodies.
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Cloning
The fragments corresponding to the deletion mutants of the VE-cadherin À2486/ þ 24 promoter region were amplified by PCR using the À2486Luc vector as template (100 ng) mixed with native Pfu (5 U, Stratagene, Amsterdam, The Netherlands), 0.31 mM dNTP, 1 mM forward oligonucleotide (see below) and 1 mM 5 0 -CTTTCTTTATGTTTT TGGCGTCTT reverse primer in the recommended buffer. PCR were 45 s at 951C, followed by 25 cycles of 45 s at 951C, 45 s at 551C, 4.5 min at 721C and a final extension step at 721C for 7 min. PCR fragments were gel purified, digested with XhoI and SstI and cloned into the corresponding sites of the pGL3 basic vector. The forward primers used were as follows: À2110Luc ACTGAGCTCCAGTGCTACTCCCTCG; -1726Luc ACTG AGCTCTCCACTGAGTACACAG; -1531Luc ACT GAGCT CGTAGTTGAATGCTATG; -830Luc ACTGAGCTCTGGC TGAATGAAGAGA; -515LucACTGAGCTCTCTCAGCTG CCCGACT. The À600Luc reporter vector was prepared by digestion of À2486Luc with KpnI and XhoI and insertion of the 600 bp fragment into corresponding sites of the pGL3 basic vector.
VEGF gene fragments containing (VEGF HRE þ Luc) or not (VEGF HREÀ Luc) the HRE were cloned by PCR amplification of mouse genomic DNA (100 ng, Invitrogen/Clontech) mixed with Pfu Turbo (12.5 u), 2.5 ml DMSO in recommended buffer in a final volume of 50 ml. Forward primers used were 5 0 -ATG GTACCTGCCAGACTACACAGTGCATACGTG (2 mM) or 5 0 -ATGGTA CCCGTCTCACTCCCCGCCACTGACTAA (2 mM), respectively. The reverse primer used was 5 0 -TAGC TAGCAAGCCTCTGCGCTTCTCACCGGTAA(2 mM). PCR were 941C for 2 min followed by 35 cycles of 941C for 30 s, 651C for 30 s, 721C for 1.5 min and a final extension step at 721C for 7 min. The approximate 900 bp products were gel purified, digested with KpnI and NheI and cloned into the corresponding sites of the pGL3 basic vector using standard procedures (Sambrook et al., 1989) . In all cases, vectors were used to transform Novablue competent cells (Novagen), which were selected on LB-agar plates containing 70 mg/ml carbenicillin. Several positive clones were picked, the plasmids purified and the cloned inserts sequenced on both strands. One correct clone was arbitrarily chosen for the experiments.
PCR analyses
Total RNA were extracted from cell monolayers using the RNAeasy kit (Quiagen, Courtaboeuf, France). Reverse transcription was performed as described earlier (Lelie`vre et al., 2000) . PCR were setup by mixing RT products (corresponding to 50 ng total RNA) with LC FastStart DNA Master SYBR Green I, 3 mM MgCl 2 (Roche), forward and reverse primers (50 nM each) as listed below. The reactions mixes were heated for 10 min at 951C and 40 cycles of 20 s at 951C, 8 s at annealing temperature and 30 s at 721C were performed using a LightCycler 2.0 (Roche). A fusion curve was determined after each reaction. Forward and reverse PCR primers, annealing temperatures and cycle number were as follows: VE-cadherin 5 0 -TTGCCCAGCCCTACGAACCTA AAG, 5 0 -ACCACCGCCCTCCTCATCGTAAGT, 601C; V EGF 5 0 -CACTGGACCCTGGCTTTACTGC, 5 0 -CGCCTCG GCTTGTCACA, 601C; actin, 5 0 -CGGTGACGGGGTCA CCCACA, 5 0 -AAGCATTTGCGGTGGACGAT, 651C. Relative quantification was based on the crossing-point (Cp) values with the 'Fit Point' method. Results were obtained using the DDC p method, where DC p is target/reference C p ratio and DDC p is sample/calibrator DC p ratio, according to manufacturer's specifications.
EMSA EMSA were performed as described earlier (Lelie`vre et al., 2000; Lelie`vre et al., 2002) . Double-stranded DNA probes were prepared from synthetic DNA oligolucleotides corresponding to the following (5 0 to 3 0 , forward strand): HRE1wt; TTGTCTGTCACGTTTCTCAG, HRE1mt; TTGTCTGTCT TTTTTCTCAG, HRE2wt; CATGGTCACGTGAAGCCCAT, HRE2mt; CATGGTCAAAAGAAGCCCAT, HRE3 (À839wt); GCGCCACCACGCCTGGCTGA, ÀHRE3 (À839)mt; GC GCCACCTTTCCTGGCTGA, HRE3 (À849)wt; GATTAAAG GCGTGCGCCACC, ÀHRE3 (À849)mt; GATTAAAGGAA AGCGCCACC, HRE4wt; ACGCACGCACGCACGCACGC, HRE4mt; TTTCTTTCTTTCTTTCTTTC, HRE5wt; CCTGG CAGACGTGTCCACTG, HRE5mt; CCTGGCAGAAAA GTCCACTG, HRE6wt; CCTCCAGCACGCTCAGTGCT, HRE6mt; CCTCCAGCTTTCTCAGTGCT. H5 V cells were cultured in normoxia or hypoxia for 16 h after which time cell nuclear extracts were prepared and quantified. Nuclear extracts (5 mg) from normoxic or hypoxic cells were mixed with the 32 Plabelled or unlabelled double-stranded DNA probes corresponding to the various HRE and with or without antibodies directed against HIF-1a or HIF-2a (Novus Biologicals) and analysed on 6% PAGE. Gels were dried and autoradiographed.
